Metastatic Urothelial Cancer: a rapidly changing treatment landscape-Reference-Cited by-同舟云学术

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Published:2021-01 Issue: Volume:13 Page:175883592110473
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Stecca Carlos¹^ORCID,Abdeljalil Osama¹,Sridhar Srikala S.²

Affiliation:

1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

2. Professor, University of Toronto, Medical Oncologist, Princess Margaret Cancer Center, Chair, GU Medical Oncologists of Canada, 7-625 -700 University Avenue, Toronto, ON M5G 2M9, Canada

Abstract

Despite significant progress, metastatic urothelial cancer remains an incurable condition with a limited life expectancy. Platinum-based chemotherapy is still the mainstay of treatment for metastatic disease, but immunotherapy, antibody drug conjugates, and targeted agents have shown encouraging results in several recent practice changing trials. In this review, we discuss the standard of care, recent therapeutic advances, ongoing clinical trials, and future perspectives in metastatic urothelial carcinoma.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/17588359211047352

Reference78 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

3. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

4. Molecular biology and targeted therapies for urothelial carcinoma

5. Chromosome Instability and Progression in Urothelial Cell Carcinoma of the Bladder

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Literature Review and Network Meta-Analysis;Clinical Genitourinary Cancer;2024-12

2. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma;Journal of Health Economics and Outcomes Research;2024-08-20

4. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma;Journal of Health Economics and Outcomes Research;2024-08-20

5. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer;European Journal of Medical Research;2024-07-29